Brilliant Violet 605™ anti-mouse CD279 (PD-1) Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

PD-1 cDNA followed by PD-1-Ig fusion protein

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.

Concentration

µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue³, in vivo blocking of PD-1 binding to its ligands^2,3, and spatial biology (IBEX)^5,6.

Application References

(PubMed link indicates BioLegend citation)

1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
2. Wrzner K, et al. 2021. EBioMedicine. 63:103197. PubMed
3. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
4. Lee JH, et al. 2022. Cell Rep. 38:110485. PubMed
5. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
6. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
7. Eschweiler S 2023. Cell Reports. 42(2):112040. PubMed
8. Stravokefalou V, et al. 2023. Front Immunol. 13:1014802. PubMed
9. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
10. van Elsas MJ, et al. 2023. J Immunother Cancer. 11:. PubMed
11. Verma S, et al. 2016. J Virol. 90: 650 - 658. PubMed
12. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
13. Wang D, et al. 2018. Immunity. 48:659. PubMed
14. Stathopoulou C, et al. 2020. Immunity. 49(2):247-263.e7.. PubMed
15. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
16. Baram T, et al. 2021. Cells. 10:. PubMed
17. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
18. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
19. Lindenstrøm T et al. 2017. EBioMedicine. 27:27-39 . PubMed
20. DeLong JH, et al. 2019. Immunohorizons. 3:13. PubMed
21. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
22. Rodriguez AB, et al. 2021. Cell Reports. 36(3):109422. PubMed
23. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
24. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
25. Marro BS, et al. 2019. Cell Rep. 29:3293. PubMed
26. Levi J, et al. 2020. J Nucl Med. . PubMed
27. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
28. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
29. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
30. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
31. Xu S, et al. 2021. Immunity. . PubMed
32. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
33. Kurniawan H, et al. 2020. Cell Metabolism. 31(5):920-936. PubMed
34. Vogel AB, et al. 2021. Nature. 592:283. PubMed
35. Tan X, et al. 2021. Sci Adv. 7: . PubMed
36. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
37. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
38. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
39. Sandu I, et al. 2020. Cell Reports. 32(8):108078. PubMed
40. Fu Y, et al. 2021. Front Cell Dev Biol. 9:689727. PubMed
41. Engel I, et al. 2016. Nat Immunol. 10.1038/ni.3437. PubMed
42. Wen J, et al. 2020. Cell Rep. 31:107566. PubMed
43. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
44. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
45. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
46. Gangoso E, et al. 2021. Cell. 184:2454. PubMed

RRID

AB_2562616 (BioLegend Cat. No. 135219)
AB_2562616 (BioLegend Cat. No. 135220)

Antigen Details

Structure

A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.

Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function

Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.

Ligand/Receptor

B7-H1 (PD-L1) and B7-DC (PD-L2)

Cell Type

B cells, T cells

Biology Area

Cancer Biomarkers, Immunology, Inhibitory Molecules

Molecular Family

CD Molecules, Immune Checkpoint Receptors

Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID

18566 View all products for this Gene ID

Specificity (DOES NOT SHOW ON TDS):

CD279

Specificity Alt (DOES NOT SHOW ON TDS):

PD-1

App Abbreviation (DOES NOT SHOW ON TDS):

FC

UniProt

View information about CD279 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

Other Formats

Certificate of Analysis